Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Febuxostat
Adenuric
Routinely available
SMC (637/10)
29/03/2023
Indication
Chronic hyperuricaemia
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
80mg, 120mg tablets
Comments
-